Pagan Douglas W.

SEC source: 0001193125-26-164210 · ownership.xml · derivative · entry 2

Pagan Douglas W. · CIK 0001628880 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2036-04-16

F2 · derivative.exercise_date: The options vest and become exercisable, if at all, as to all of the underlying shares if (i) the average daily closing price of the Company's common stock on Nasdaq during any 30 consecutive calendar-day period during the period beginning October 16, 2026 and ending on April 16, 2030 (the "Performance Measurement Period"), or (ii) the stock price in a change in control transaction that occurs during the Performance Measurement Period, equals or exceeds $40 per share, in each case subject to the Reporting Person's continued service through such vesting date.

SEC source: 0001193125-26-164210 · ownership.xml · derivative · entry 1

Pagan Douglas W. · CIK 0001628880 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2036-04-16

F1 · derivative.exercise_date: The options vest and become exercisable as to 25% of the underlying shares on April 16, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date.

SEC source: 0001399529-21-000203 · wf-form4_164081286902607.xml · derivative · entry 5

Pagan Douglas W. · CIK 0001628880 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 36,900 shares

Expires not disclosed

F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting).

F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting).

F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting).

SEC source: 0001399529-21-000203 · wf-form4_164081286902607.xml · derivative · entry 4

Pagan Douglas W. · CIK 0001628880 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 95,650 shares

Expires not disclosed

F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting).

F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting).

F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting).

SEC source: 0001399529-21-000203 · wf-form4_164081286902607.xml · derivative · entry 3

Pagan Douglas W. · CIK 0001628880 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,150 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one Share.

F3 · price: At the Effective Time, each Issuer RSU that was then outstanding was cancelled and converted into the right to receive a cash payment equal to (A) the Offer Price multiplied by (B) the total number of Shares subject to such Issuer RSU immediately prior to the Effective Time (without regard to vesting).

F3 · derivative.exercise_date: At the Effective Time, each Issuer RSU that was then outstanding was cancelled and converted into the right to receive a cash payment equal to (A) the Offer Price multiplied by (B) the total number of Shares subject to such Issuer RSU immediately prior to the Effective Time (without regard to vesting).

F3 · derivative.expiration_date: At the Effective Time, each Issuer RSU that was then outstanding was cancelled and converted into the right to receive a cash payment equal to (A) the Offer Price multiplied by (B) the total number of Shares subject to such Issuer RSU immediately prior to the Effective Time (without regard to vesting).

SEC source: 0001399529-21-000203 · wf-form4_164081286902607.xml · derivative · entry 2

Pagan Douglas W. · CIK 0001628880 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,475 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one Share.

F3 · price: At the Effective Time, each Issuer RSU that was then outstanding was cancelled and converted into the right to receive a cash payment equal to (A) the Offer Price multiplied by (B) the total number of Shares subject to such Issuer RSU immediately prior to the Effective Time (without regard to vesting).

F3 · derivative.exercise_date: At the Effective Time, each Issuer RSU that was then outstanding was cancelled and converted into the right to receive a cash payment equal to (A) the Offer Price multiplied by (B) the total number of Shares subject to such Issuer RSU immediately prior to the Effective Time (without regard to vesting).

F3 · derivative.expiration_date: At the Effective Time, each Issuer RSU that was then outstanding was cancelled and converted into the right to receive a cash payment equal to (A) the Offer Price multiplied by (B) the total number of Shares subject to such Issuer RSU immediately prior to the Effective Time (without regard to vesting).

SEC source: 0001399529-21-000203 · wf-form4_164081286902607.xml · nonDerivative · entry 1

Pagan Douglas W. · CIK 0001628880 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 17, 2021, by and among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NNUS New Research, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Novo ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.0001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of December 28, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $38.25 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.

F1 · shares: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 17, 2021, by and among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NNUS New Research, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Novo ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.0001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of December 28, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $38.25 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.

F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 17, 2021, by and among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NNUS New Research, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Novo ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.0001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of December 28, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $38.25 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.

SEC source: 0001399529-21-000178 · wf-form4_163977589128508.xml · derivative · entry 3

Pagan Douglas W. · CIK 0001628880 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,150

Underlying: Common Stock · 2,050 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Common Stock.

F4 · derivative.exercise_date: The RSUs vest over a period of four years, with 25% of the RSUs vesting on each of the first, second, third and fourth anniversaries of December 15, 2020, subject in each case to the Reporting Person's continued employment or service with the Issuer through the applicable vesting date.

F4 · derivative.expiration_date: The RSUs vest over a period of four years, with 25% of the RSUs vesting on each of the first, second, third and fourth anniversaries of December 15, 2020, subject in each case to the Reporting Person's continued employment or service with the Issuer through the applicable vesting date.

SEC source: 0001399529-21-000178 · wf-form4_163977589128508.xml · nonDerivative · entry 2

Pagan Douglas W. · CIK 0001628880 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,775

F3 · shares: Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs.

SEC source: 0001399529-21-000178 · wf-form4_163977589128508.xml · nonDerivative · entry 1

Pagan Douglas W. · CIK 0001628880 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,377

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Common Stock.

F2 · balance_after: Includes shares acquired under the DRNA 2014 Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(c).

SEC source: 0001399529-21-000121 · wf-form4_162398020794290.xml · derivative · entry 3

Pagan Douglas W. · CIK 0001628880 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,475

Underlying: Common Stock · 6,825 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Common Stock.

F4 · derivative.exercise_date: Represents RSUs that vest over a period of four years, with 25% of the RSUs vesting on each of the first, second, third and fourth anniversaries of June 15, 2020, subject in each case to the Reporting Person's continued employment or service with the Issuer through the applicable vesting date.

F4 · derivative.expiration_date: Represents RSUs that vest over a period of four years, with 25% of the RSUs vesting on each of the first, second, third and fourth anniversaries of June 15, 2020, subject in each case to the Reporting Person's continued employment or service with the Issuer through the applicable vesting date.

SEC source: 0001399529-21-000121 · wf-form4_162398020794290.xml · nonDerivative · entry 2

Pagan Douglas W. · CIK 0001628880 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,760

F3 · shares: Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs.

F2 · balance_after: Includes shares acquired under the DRNA 2014 Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3(c).

SEC source: 0001399529-21-000121 · wf-form4_162398020794290.xml · nonDerivative · entry 1

Pagan Douglas W. · CIK 0001628880 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,764

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Common Stock.

F2 · balance_after: Includes shares acquired under the DRNA 2014 Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3(c).

SEC source: 0001399529-21-000011 · wf-form4_161050543678371.xml · derivative · entry 2

Pagan Douglas W. · CIK 0001628880 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,900

Underlying: Common Stock · 36,900 shares

Expires 2031-01-11

F3 · derivative.exercise_date: The option vests in 48 substantially equal monthly installments, with the first installment vesting on the last day of January 2021, and the remaining shares vesting on the last day of each of the 47 months thereafter; subject in each case to the Reporting Person's continued employment or service with the Issuer through each applicable vesting date.

SEC source: 0001399529-21-000011 · wf-form4_161050543678371.xml · derivative · entry 1

Pagan Douglas W. · CIK 0001628880 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,200

Underlying: Common Stock · 8,200 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Common Stock.

F2 · derivative.exercise_date: The RSUs vest over a period of four years, with 25% of the RSUs vesting on each of the first, second, third and fourth anniversaries of December 15, 2020, subject in each case to the Reporting Person's continued employment or service with the Issuer through the applicable vesting date.

F2 · derivative.expiration_date: The RSUs vest over a period of four years, with 25% of the RSUs vesting on each of the first, second, third and fourth anniversaries of December 15, 2020, subject in each case to the Reporting Person's continued employment or service with the Issuer through the applicable vesting date.

SEC source: 0000899243-20-014950 · doc4.xml · derivative · entry 2

Pagan Douglas W. · CIK 0001628880 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,650

Underlying: Common Stock · 95,650 shares

Expires 2030-05-31

F2 · derivative.exercise_date: The options vest 25% on the first year anniversary of the vesting start date of May 26, 2020 and the remaining 75% vest in 36 substantially equal monthly installments thereafter, subject in each case to the Reporting Person's continued employment or service with the Issuer through the applicable vesting date.

SEC source: 0000899243-20-014950 · doc4.xml · derivative · entry 1

Pagan Douglas W. · CIK 0001628880 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,300

Underlying: Common Stock · 27,300 shares

Expires not disclosed

F1 · derivative.exercise_price: Represents restricted stock units ("RSUs") that vest over a period of four years, with 25% of the RSUs vesting on each of the first, second, third and fourth anniversaries of June 15, 2020, subject in each case to the Reporting Person's continued employment or service with the Issuer through the applicable vesting date. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock.

F1 · derivative.exercise_date: Represents restricted stock units ("RSUs") that vest over a period of four years, with 25% of the RSUs vesting on each of the first, second, third and fourth anniversaries of June 15, 2020, subject in each case to the Reporting Person's continued employment or service with the Issuer through the applicable vesting date. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock.

F1 · derivative.expiration_date: Represents restricted stock units ("RSUs") that vest over a period of four years, with 25% of the RSUs vesting on each of the first, second, third and fourth anniversaries of June 15, 2020, subject in each case to the Reporting Person's continued employment or service with the Issuer through the applicable vesting date. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0001209191-20-001183 · doc4.xml · derivative · entry 3

Pagan Douglas W. · CIK 0001628880 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,281

Underlying: Common Stock · 25,281 shares

Expires 2029-12-31

F3 · derivative.exercise_date: 100% of the shares subject to the option vest on December 31, 2020, subject to Reporting Person's continuous service with the Issuer through such date.

SEC source: 0001209191-20-001183 · doc4.xml · nonDerivative · entry 2

Pagan Douglas W. · CIK 0001628880 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,943

F2 · shares: Represents shares withheld to satisfy withholding tax obligations upon the vesting of a restricted stock grant.

SEC source: 0001209191-20-001183 · doc4.xml · nonDerivative · entry 1

Pagan Douglas W. · CIK 0001628880 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,997

F1 · shares: 15,890 shares vest on 12/31/2020.

SEC source: 0000904454-19-000351 · edgar.xml · nonDerivative · entry 5

Pagan Douglas W. · CIK 0001628880 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,807

F5 · shares: Represents RSUs granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan, pursuant to the Consulting Agreement, dated March 15, 2019, between the Issuer and the Reporting Person. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on December 23, 2019, subject to the Reporting Person's material compliance with the Consulting Agreement and the execution of a customary release.

SEC source: 0000904454-19-000351 · edgar.xml · nonDerivative · entry 4

Pagan Douglas W. · CIK 0001628880 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,807

F4 · shares: Represents forfeiture of PRSUs in connection with the Reporting Person's resignation as CFO of the Issuer, which were granted on February 14, 2018 and previously reporting in Table I.

SEC source: 0000904454-19-000351 · edgar.xml · nonDerivative · entry 3

Pagan Douglas W. · CIK 0001628880 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,057

F3 · shares: Represents forfeiture of performance-based RSUs ("PRSUs") in connection with the Reporting Person's resignation as CFO of the Issuer, which were granted on August 3, 2017 and previously reported in Table I.

SEC source: 0000904454-19-000351 · edgar.xml · nonDerivative · entry 2

Pagan Douglas W. · CIK 0001628880 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 114,557

F2 · shares: Represents forfeiture of RSUs in connection with the Reporting Person's resignation as CFO of the Issuer, which were granted on February 26, 2019 and previously reported in Table I.

SEC source: 0000904454-19-000351 · edgar.xml · nonDerivative · entry 1

Pagan Douglas W. · CIK 0001628880 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 151,557

F1 · shares: Represents forfeiture of restricted stock units ("RSUs") in connection with the Reporting Person's resignation as Chief Financial Officer ("CFO") of the Issuer, which were granted on February 14, 2018 and previously reported in Table I.

SEC source: 0000904454-19-000284 · edgar.xml · nonDerivative · entry 1

Pagan Douglas W. · CIK 0001628880 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 171,057

F1 · shares: Represents restricted stock units granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest as to 1/3 of the shares subject to the restricted stock units on December 10, 2019, and on the same calendar date of each successive year thereafter until fully vested, subject to the Reporting Person's continued service with the Issuer through each vesting date.

SEC source: 0000904454-19-000180 · edgar.xml · nonDerivative · entry 1

Pagan Douglas W. · CIK 0001628880 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 134,057

F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock unit award, pursuant to Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $6.72 to $6.85. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2 to this Form 4.

SEC source: 0000904454-19-000151 · edgar.xml · nonDerivative · entry 1

Pagan Douglas W. · CIK 0001628880 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 136,552

F1 · shares: Represents performance-based restricted stock units ("PRSUs") granted on February 14, 2018 to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan, which were earned on February 1, 2019. These PRSUs will settle in shares of Common Stock on May 8, 2020, provided that the Reporting Person remains in continuous service with Paratek Pharmaceuticals, Inc. through the settlement date.

SEC source: 0001209191-19-000589 · doc4.xml · derivative · entry 2

Pagan Douglas W. · CIK 0001628880 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,350

Underlying: Common Stock · 63,350 shares

Expires 2028-12-31

F2 · derivative.exercise_date: 63,350 options vest on 12/31/2019.

SEC source: 0001209191-19-000589 · doc4.xml · nonDerivative · entry 1

Pagan Douglas W. · CIK 0001628880 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,107

F1 · shares: 40,107 shares vest on 12/31/2019.

SEC source: 0000904454-18-000787 · edgar.xml · nonDerivative · entry 1

Pagan Douglas W. · CIK 0001628880 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 120,302

F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock unit award, pursuant to Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $6.55 to $7.15. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2 to this Form 4.

SEC source: 0000904454-18-000667 · edgar.xml · nonDerivative · entry 2

Pagan Douglas W. · CIK 0001628880 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 123,220

F2 · shares: Sale of shares to cover personal income tax obligations upon vesting of PRSUs, pursuant to Rule 10b5-1 trading plan.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $8.93 to $9.02. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 3 to this Form 4.

SEC source: 0000904454-18-000667 · edgar.xml · nonDerivative · entry 1

Pagan Douglas W. · CIK 0001628880 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 126,004

F1 · shares: Represents performance-based restricted stock units ("PRSUs") granted on February 14, 2018 to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan that vested on October 12, 2018.

SEC source: 0000904454-18-000644 · edgar.xml · nonDerivative · entry 3

Pagan Douglas W. · CIK 0001628880 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 119,504

F3 · shares: Sale of shares to cover personal income tax obligations upon vesting of PRSUs, pursuant to Rule 10b5-1 trading plan.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $9.75 to $9.95. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 4 to this Form 4.

SEC source: 0000904454-18-000644 · edgar.xml · nonDerivative · entry 2

Pagan Douglas W. · CIK 0001628880 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 127,083

F2 · shares: Represents PRSUs granted on August 3, 2017 to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan that vested on October 2, 2018. These PRSUs will settle in shares of common stock on October 2, 2019, provided that the Reporting Person remains in continuous service with Paratek Pharmaceuticals, Inc. through the settlement date.

SEC source: 0000904454-18-000644 · edgar.xml · nonDerivative · entry 1

Pagan Douglas W. · CIK 0001628880 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,583

F1 · shares: Represents performance-based restricted stock units ("PRSUs") granted on February 2, 2017 to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan that vested on October 2, 2018.

SEC source: 0001209191-18-051786 · doc4.xml · derivative · entry 1

Pagan Douglas W. · CIK 0001628880 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2028-09-18

F1 · derivative.exercise_date: 25,000 shares shall vest on each of 9/18/2019 and 9/18/2020.

SEC source: 0000904454-18-000289 · edgar.xml · nonDerivative · entry 1

Pagan Douglas W. · CIK 0001628880 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,083

F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of performance-based restricted stock units, pursuant to Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $12.60 to $12.85. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2 to this Form 4.

SEC source: 0000904454-18-000273 · edgar.xml · nonDerivative · entry 1

Pagan Douglas W. · CIK 0001628880 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,320

F1 · shares: Represents performance-based restricted stock units granted on February 2, 2017 to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan that vested on April 3, 2018.

SEC source: 0000904454-18-000187 · edgar.xml · nonDerivative · entry 1

Pagan Douglas W. · CIK 0001628880 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,820

F1 · shares: Represents restricted stock units granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest as to 1/3 of the shares subject to the restricted stock units on December 10, 2018, and on the same calendar date of each successive year thereafter until fully vested, subject to the Reporting Person's continued service with the Issuer through each vesting date.

SEC source: 0000904454-18-000131 · edgar.xml · nonDerivative · entry 1

Pagan Douglas W. · CIK 0001628880 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,570

F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock unit award, pursuant to Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.43, inclusive. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000904454-17-000497 · edgar.xml · nonDerivative · entry 2

Pagan Douglas W. · CIK 0001628880 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,861

F2 · shares: Sale of shares to cover personal income tax obligations upon vesting of performance-based restricted stock units, pursuant to Rule 10b5-1 trading plan.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.45 to $23.90, inclusive. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.

SEC source: 0000904454-17-000497 · edgar.xml · nonDerivative · entry 1

Pagan Douglas W. · CIK 0001628880 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

F1 · shares: Represents performance-based restricted stock units granted on February 2, 2017 to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan that vested on July 3, 2017.

SEC source: 0000904454-17-000450 · edgar.xml · nonDerivative · entry 1

Pagan Douglas W. · CIK 0001628880 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,000

F1 · kind: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0000904454-17-000137 · edgar.xml · nonDerivative · entry 6

Pagan Douglas W. · CIK 0001628880 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,595

F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock unit award, pursuant to Rule 10b5-1 trading plan.

SEC source: 0000904454-17-000137 · edgar.xml · nonDerivative · entry 5

Pagan Douglas W. · CIK 0001628880 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,620

F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock unit award, pursuant to Rule 10b5-1 trading plan.

SEC source: 0000904454-17-000137 · edgar.xml · nonDerivative · entry 4

Pagan Douglas W. · CIK 0001628880 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,806

F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock unit award, pursuant to Rule 10b5-1 trading plan.

SEC source: 0000904454-17-000137 · edgar.xml · nonDerivative · entry 3

Pagan Douglas W. · CIK 0001628880 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,823

F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock unit award, pursuant to Rule 10b5-1 trading plan.

SEC source: 0000904454-17-000137 · edgar.xml · nonDerivative · entry 2

Pagan Douglas W. · CIK 0001628880 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,251

F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock unit award, pursuant to Rule 10b5-1 trading plan.

SEC source: 0000904454-17-000137 · edgar.xml · nonDerivative · entry 1

Pagan Douglas W. · CIK 0001628880 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,983

F1 · shares: Sale of shares to cover personal income tax obligations upon vesting of restricted stock unit award, pursuant to Rule 10b5-1 trading plan.